David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, David was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Bioventus, Detector Technologies, Gyros Protein Technologies and MedPharm. His prior Board Directorships have included Avista Pharma, ACLARA Biosciences, Assay Designs, NOVEX, Roadrunner Pharmacy and Signature Genomic Laboratories. David currently heads Ampersand’s European office, which is based in Amsterdam.